The case for & against
Bull & Bear analysis
CNO Financial Group (NYSE: CNO) is an established player in the insurance and financial services sector, focusing predominantly on providing life, health, and retirement products to middle-income consumers. Through its two main divisions—Consumer and Worksite Insurance—CNO has carved out a strong market position aimed at addressing the specific needs of underserved demographics. The company continues to adapt to changing consumer preferences, notably shifting focus towards Medicare Supplement plans, as a demographic shift sees around 11,000 Americans turning 65 every day, enhancing demand for retirement-related products.
Bull says
- ↑Q1 2026 operating EPS rose 33% YoY to $1.05
- ↑New annualized premiums increased 11% in Q1 2026
- ↑Returned $60 M in buybacks, cutting shares by 7%
- ↑Dividend grew ~10% annually over past decade
- ↑2026 FCF guidance of $200–250 M supports cash returns
- ↑Strong earnings yield and favorable rate sensitivity
Bear says
- ↓Insiders sold over $5 M, raising governance concerns
- ↓Shares trade ~31% above fair value with 20.8× P/E
- ↓Negative growth revisions amid Medicare Advantage headwinds
- ↓Rising MedSupp claims ratios pressuring margins
- ↓Credit market and rate volatility risk investment returns
- ↓Low institutional ownership and sales growth risks
Investment themes with CNO
Companies paying above-average dividends
Companies repurchasing their own shares
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- operating earnings per share were $1.05 for the quarter, up 33%, and up 42%, excluding significant items in the prior period, reflecting continued profitable sales growth, strength in underwriting results, growth in net investment income driven by growth in assets together with higher yields, and ongoing discipline in expense and capital management.
- $60 million of excess capital on share repurchases, contributing to a 7% reduction in weighted average diluted shares outstanding.
- On a trailing 12-month basis, operating return on equity was 13.1% and 12.2%, excluding significant items.
Bear points
- The expense ratio was 18.9%, reflecting lower than planned spending in the quarter, which we expect to normalize over the balance of the year.
- Medicare Supplement faced modestly adverse claims experience, partially offset by the favorable impact of continued growth.
- During the 2025 AEP, industry-wide MA enrollment growth slowed to about 3%, the weakest pace in 20 years.